Clinical Trial

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Study acronym: DAHLIA
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-11-05; most recent amendment 2026-05-06.
Trial Details
NCT Number NCT06678659
Lead Sponsor Recursion Pharmaceuticals Inc.
Conditions Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas
Enrollment 170 participants
Start Date 2024-11-21
Primary Completion 2028-10-30 (estimated)
Study Completion 2028-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-08